Latest News

Leidos Holdings (LDOS) posted 16.9% earnings growth for the past year, outpacing its five-year average of 13.7% per year. Net profit margin also improved to 8.1% from last year’s 7.4%, while management continues to deliver high-quality results. Looking ahead, consensus expects earnings to increase by 3.5% per year and revenue by 2.7%, both trailing the broader U.S. market averages. See our full analysis for Leidos Holdings. Next, we will see how these headline numbers compare to the current...

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Ideally, a...

Castle Biosciences (CSTL) continues to operate at a loss, with recent filings confirming the company has yet to achieve net profit margin improvement over the past year and is still generating negative earnings. Despite reducing its annual losses at a rate of 9.6% per year over the last five years, it remains on a slower growth path. Forecasted revenue is expected to rise 6.5% per year, lagging behind the broader US market’s 10.5% annual growth rate. With profitability still out of reach in...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

Pet Valu Holdings (TSX:PET) reported a profit margin of 8.5%, up from 8% last year, with earnings growing at 11.6% in the most recent year. This outpaced its five-year average growth of 9.6% per year. Revenue and earnings are both expected to expand faster than the Canadian market, with forecasts of 6.9% and 15.2% annual growth respectively. Investors are likely to view these results, alongside improved margins and a current P/E ratio of 21.1x that sits below the peer group average, as...

Indraprastha Medical Corporation Limited ( NSE:INDRAMEDCO ) shareholders have had their patience rewarded with a 31...

LGI Homes (LGIH) reported a 20.4% annual decline in earnings over the past five years, with current net profit margins at 5.9% compared to 8.8% previously. However, revenue is projected to grow at 17.4% per year, while EPS is expected to jump by 27.4% annually for the next three years, outpacing the broader US market’s 16% outlook. With margins under recent pressure but robust growth prospects ahead, investors will be weighing risks from declining profitability against strong forward-looking...

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...

Key Insights Institutions' substantial holdings in S.J.S. Enterprises implies that they have significant influence over...

To the annoyance of some shareholders, Jay Bee Laminations Limited ( NSE:JAYBEE ) shares are down a considerable 33% in...

Rhythm Pharmaceuticals (RYTM) reported widening losses, with net losses having grown at a rate of 18.8% per year over the past five years. Despite being unprofitable, the company commands a Price-To-Sales Ratio of 40x, outpacing both the US Biotechs industry average of 10.8x and the peer average of 17.9x, positioning its stock as highly valued on these multiples. On the growth front, forecasts point to revenue expanding at 45.8% per year and earnings projected to grow 70.56% per year, with...

ACC Limited ( NSE:ACC ) just released its latest second-quarter results and things are looking bullish. ACC delivered a...

Wajax (TSX:WJX) reported net profit margins of 2.2%, down from 2.5% in the prior year, as the company faced a contraction in margin performance. Over the past twelve months, earnings growth turned negative, and revenue is projected to decline at a rate of 0.2% per year over the next three years. Still, Wajax has built a 3.7% annual earnings growth rate over the last five years, which highlights a longer-term trend of improvement despite recent setbacks. See our full analysis for Wajax. Up...

PRA Group (PRAA) is currently unprofitable, with losses having grown at an average annual rate of 48.8% over the last five years. While revenue is projected to grow at 6.6% per year, this is slower than the broader US market’s pace of 10.5% per year. The company is expected to remain unprofitable for at least the next three years. Margins have seen no improvement over the past year, signaling that profitability remains a persistent challenge for investors considering this stock. See our full...

Clean Science and Technology (NSE:CLEAN) has had a rough three months with its share price down 18%. However, stock...

Key Insights Significant control over Nesco by private companies implies that the general public has more power to...

With a median price-to-sales (or "P/S") ratio of close to 2.3x in the Infrastructure industry in India, you could be...

Last week's profit announcement from Raymond Realty Limited ( NSE:RAYMONDREL ) was underwhelming for investors, despite...

If you're looking for a multi-bagger, there's a few things to keep an eye out for. Firstly, we'd want to identify a...

What trends should we look for it we want to identify stocks that can multiply in value over the long term? Ideally, a...

Dynamatic Technologies Limited's ( NSE:DYNAMATECH ) price-to-sales (or "P/S") ratio of 4x may look like a poor...

The subdued market reaction suggests that NIIT Limited's ( NSE:NIITLTD ) recent earnings didn't contain any surprises...

Key Insights The considerable ownership by private companies in Repco Home Finance indicates that they collectively...